Alliance for Pandemic Preparedness

June 15, 2020

First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia

Category:

Topic:

  • [pre-print, not peer reviewed] Temesgen et al. reported the use of lenzilumab, an anti- GM-CSF monoclonal antibody, in 12 patients with severe COVID-19 pneumonia. Of the 12 treated patients, 11 (92%) patients had significantly improved clinical outcomes. There were no treatment-related adverse events and no deaths.  

Temesgen et al. (June 12, 2020). First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia. Pre-print downloaded June 15 from https://doi.org/10.1101/2020.06.08.20125369